PFE Quote, Financials, Valuation and Earnings

Arvinas has a net margin of 2.31% compared to Pfizer's net margin of -76.18%. Pfizer's return on equity of 8.91% beat Arvinas's return on equity of -32.96%.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 21.76%. On the other hand Arvinas has an analysts' consensus of $45.26 which suggests that it could grow by 436.93%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Arvinas has a beta of 1.954, suggesting its more volatile than the S&P 500 by 95.435%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.57%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Arvinas quarterly revenues of $59.2M. Pfizer's net income of $410M is higher than Arvinas's net income of -$45.1M. Notably, Pfizer's price-to-earnings ratio is 18.24x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.30x versus 2.30x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 2.31% compared to Pfizer's net margin of -117.16%. Pfizer's return on equity of 8.91% beat Moderna's return on equity of -29.09%.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 21.76%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.57%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Moderna quarterly revenues of $956M. Pfizer's net income of $410M is higher than Moderna's net income of -$1.1B. Notably, Pfizer's price-to-earnings ratio is 18.24x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.30x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 2.31% compared to Pfizer's net margin of 24.22%. Pfizer's return on equity of 8.91% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 21.76%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.57%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Pfizer pays 118.44% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Pfizer's net income of $410M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Pfizer's price-to-earnings ratio is 18.24x while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.30x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 2.31% compared to Pfizer's net margin of --. Pfizer's return on equity of 8.91% beat Viking Therapeutics's return on equity of --.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 21.76%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.57%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Viking Therapeutics quarterly revenues of --. Pfizer's net income of $410M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Pfizer's price-to-earnings ratio is 18.24x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.30x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.